BR112022021395A2 - Compostos antagonistas de h4 - Google Patents

Compostos antagonistas de h4

Info

Publication number
BR112022021395A2
BR112022021395A2 BR112022021395A BR112022021395A BR112022021395A2 BR 112022021395 A2 BR112022021395 A2 BR 112022021395A2 BR 112022021395 A BR112022021395 A BR 112022021395A BR 112022021395 A BR112022021395 A BR 112022021395A BR 112022021395 A2 BR112022021395 A2 BR 112022021395A2
Authority
BR
Brazil
Prior art keywords
antagonist compounds
azetidinylpyrimidin
histamine
ameliorating
receptors
Prior art date
Application number
BR112022021395A
Other languages
English (en)
Portuguese (pt)
Inventor
Stuart Congreve Miles
Fieldhouse Charlotte
Alan Swain Nigel
Pickworth Mark
Robert Hannah Duncan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70859977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022021395(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of BR112022021395A2 publication Critical patent/BR112022021395A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022021395A 2020-04-22 2021-04-22 Compostos antagonistas de h4 BR112022021395A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005858.2A GB202005858D0 (en) 2020-04-22 2020-04-22 H4 Antagonist compounds
PCT/GB2021/050971 WO2021214469A1 (en) 2020-04-22 2021-04-22 H4 antagonist compounds

Publications (1)

Publication Number Publication Date
BR112022021395A2 true BR112022021395A2 (pt) 2022-12-13

Family

ID=70859977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021395A BR112022021395A2 (pt) 2020-04-22 2021-04-22 Compostos antagonistas de h4

Country Status (12)

Country Link
US (1) US20230167094A1 (https=)
EP (1) EP4139300A1 (https=)
JP (1) JP7671307B2 (https=)
KR (1) KR20230004512A (https=)
CN (1) CN115916770B (https=)
AU (1) AU2021260142A1 (https=)
BR (1) BR112022021395A2 (https=)
CA (1) CA3180853A1 (https=)
GB (1) GB202005858D0 (https=)
IL (1) IL297469A (https=)
MX (1) MX2022013340A (https=)
WO (1) WO2021214469A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) * 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
GB201817047D0 (en) * 2018-10-19 2018-12-05 Heptares Therapeutics Ltd H4 antagonist compounds

Also Published As

Publication number Publication date
CN115916770A (zh) 2023-04-04
MX2022013340A (es) 2023-02-22
JP2023522405A (ja) 2023-05-30
KR20230004512A (ko) 2023-01-06
AU2021260142A1 (en) 2022-11-17
GB202005858D0 (en) 2020-06-03
WO2021214469A1 (en) 2021-10-28
EP4139300A1 (en) 2023-03-01
CN115916770B (zh) 2025-02-28
JP7671307B2 (ja) 2025-05-01
IL297469A (en) 2022-12-01
US20230167094A1 (en) 2023-06-01
CA3180853A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112022002723A2 (pt) Métodos de tratamento de transtornos psicológicos e do cérebro
EA202091410A1 (ru) Применение антагонистов fcrn для лечения генерализованной миастении гравис
CO6440535A2 (es) Antagonistas especificos del receptor fgf-r4
BRPI0811842A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero
CR9957A (es) Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
CL2021001406A1 (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso.
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
DOP2024000179A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinación en el tratamiento del cáncer
MX2022004000A (es) Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
DOP2011000004A (es) Agentes y antagonistas fijadores de notch y metodos para el uso de los mismos
PE20091035A1 (es) Derivados de 2-aminopirimidina
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
BR112022021395A2 (pt) Compostos antagonistas de h4
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
PH12018500822A1 (en) Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
BR112017003374A2 (pt) nucleação com nucleador de compósito em bloco
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
Yu et al. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells
MX2010004880A (es) Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos.
DK3818065T3 (da) Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1
SA518392179B1 (ar) مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها
DE602005023732D1 (de) Pyrrolotriazinverbindungen
WO2022026900A3 (en) Nk receptor antagonists for cancer patients

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NXERA PHARMA UK LIMITED (GB)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements